NEW YORK, Aug. 28, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Genitourinary Drugs: Technologies and Global Marketshttp://www.reportlinker.com/p0919336/Genitourinary-Drugs-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
REPORT SCOPE
INTRODUCTION STUDY GOALS AND OBJECTIVESThis study provides a comprehensive analysis of the market for genitourinary drugs on a global basis. Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends, in order to quantify and qualify the market for drug products to treat various genitourinary diseases in both men and women. Individual drug product-types are forecast on a global basis, as are overall disease segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute the strategy to capture profit from opportunity.
The genitourinary disease drug market presents a significant part of the overall pharmaceutical product market worldwide. This study investigates the specific classes of genitourinary diseases and the pharmaceutical products for their treatment. Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease category. Continued growth is expected in emerging geographies, driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and products, strategies for accessing emerging markets, specific disease prevalence and geographies in order to allocate resources and make effective decisions.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period (2011 to 2016) are discussed. New product launches will be discussed. Revenue figures for 2010 are in an actual figure, except where actual results have not been reported due to the release timing of the report.
The report includes analysis of leading and emerging drug products for each genitourinary disease. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients with genitourinary diseases.
Market figures are based on revenues at the manufacturers' level and are projected at 2011-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market
Included in this report are forecasts by product, product category and company from 2009 through 2016. The study is arranged to offer an overview of the genitourinary disease drug market accompanied by product, company, geography and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each drug subsegment.
Where possible, epidemiological data is presented to underscore the importance of these diseases in the world population and the potential morbidity/mortality resulting from ineffective treatment of these diseases worldwide. Patent and clinical trial information is reviewed for various drugs. The status of approvals of drugs in each disease segment by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
Diagnostics for each disease area and various drugs are described. However, diagnostics are not included in market figures, as they are outside of the scope of this report.
All market share data presented is on a global basis, unless specifically noted.
INTENDED AUDIENCEThe importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition (M&A) opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including the following.
Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development and R&D.
Emerging players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their product or technology as compared to leading, competitive and emerging products. In addition, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.
Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunities and risks that are being encountered in the industry, in a product and company specific analysis.
Equity analysts are provided detailed forecasts for the next five years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts and leading individuals in the field.
The genitourinary disease drug market comprises drugs for treatment of an assortment of specific diseases in both men and women. For completeness, the current and forecast markets comprise the total market opportunity for each respective segment. Within each subsection, there are detailed forecasts for each driving mechanism, or relevant area of growth.
Information to prepare this report was obtained from participating and emerging companies in the genitourinary disease area, the American Urology Association, the American Infertility Association, the National Institute of Kidney and Urological Disease (NIDDK, NIH), the National Library of Medicine (NLM, NIH) database and the U.S. Patent and Trademark Office (USPOTP). Additional information was obtained from a variety of medical and technical journals in the various specialties of the genitourinary diseases. Other sources included the New York Times, the Wall Street Journal, the Washington Post, other newspapers and company documents, and other internet websites. Population estimates are based on those reported by the International Database of the U.S. Census Bureau. Statistical data was obtained from the World Health Organization (WHO), the National Institute of Health (NIH) and the WHO Collaborating Centre for Drug Statistics Methodology (Norway).
Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.
ANALYST CREDENTIALS Jackson Highsmith TABLE OF CONTENTSCHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGY AND INFORMATION SOURCES 3
ANALYST CREDENTIALS 4
RELATED BCC REPORTS 4
BCC ON-LINE SERVICES 4
DISCLAIMER 5
CHAPTER TWO: SUMMARY 6
SUMMARY 6
SUMMARY TABLE MAJOR GENITOURINARY DRUG CATEGORIES
REVENUE, THROUGH 2016 ($ MILLIONS)* 7
SUMMARY FIGURE MAJOR GENITOURINARY DRUG CATEGORIES
REVENUE, 2009-2016 ($ MILLIONS)* 8
CHAPTER THREE: OVERVIEW 9
DISEASES OF THE GENITOURINARY SYSTEM 9
TABLE 1 GENITOURINARY DISEASE NAMES, GENDER AND
DESCRIPTION 9
BENIGN PROSTATIC HYPERTROPHY (BPH) 9
ERECTILE DYSFUNCTION (ED) 10
INCONTINENCE (IC) 10
OVERACTIVE BLADDER (OB) 10
HORMONAL CONTRACEPTION (HC) 11
INFERTILITY (IF) 11
INFECTION (INF) 12
DRUGS GOING OFF-PATENT IN FORECAST PERIOD 12
TABLE 2 GENITOURINARY DRUGS WITH EXPIRING PATENTS,
2010-2016 13
REVENUE PROJECTION FOR GENITOURINARY DRUGS, 2011-
2016 13
TABLE 3 FIVE-YEAR PROJECTION FOR REVENUES IN
GENITOURINARY DRUG MARKET, THROUGH 2016 ($ MILLIONS) 14
REVENUE PROJECTION FOR …(CONTINUED) 15
TOP 10 BEST-SELLING GENITOURINARY DRUGS, 2011 16
TABLE 4 TOP 10 BEST-SELLING GENITOURINARY DRUGS IN 2011
($ MILLIONS/%) 16
REVENUE BY GENITOURINARY DISEASE DRUG SEGMENT 16
TABLE 5 REVENUES BY GENITOURINARY SEGMENT, 2011 ($
MILLIONS/%) 17
REVENUE FROM GENITOURINARY DRUGS BY GEOGRAPHIC
AREA 17
TABLE 6 REVENUE FROM GENITOURINARY DRUGS BY
GEOGRAPHIC AREA, 2011 ($ MILLIONS/%) 17
REVENUE FROM GENITOURINARY…(CONTINUED) 18
CHAPTER FOUR: GENITOURINARY DISEASE CONDITIONS 19
GENITOURINARY DISEASE CONDITIONS 19
BENIGN PROSTATIC HYPERTROPHY 20
TABLE 7 MAJOR DRUGS APPROVED FOR TREATMENT OF BENIGN
PROSTATIC HYPERTROPHY 21
BENIGN PROSTATIC HYPERTROPHY (CONTINUED) 22
BENIGN PROSTATIC HYPERTROPHY (CONTINUED) 23
BENIGN PROSTATIC HYPERTROPHY (CONTINUED) 24
INCONTINENCE AND OVERACTIVE BLADDER 25
INCONTINENCE AND OVERACTIVE … (CONTINUED) 26
ERECTILE DYSFUNCTION 27
TABLE 8 PRESCRIPTION DRUGS THAT HAVE AN ED WARNING 28
TABLE 9 CURRENT DRUGS FOR ERECTILE DYSFUNCTION
TRATMENT 29
INFECTION 30
TABLE 10 COMMON BACTERIAL SPECIES IN GENITOURINARY
INFECTIONS 30
INFERTILITY 31
FEMALE INFERTILITY 31
Female Infertility (Continued) 32
MALE INFERTILITY 33
Male Infertility (Continued) 34
HORMONAL CONTRACEPTION 35
ORAL CONTRACEPTIVES 35
TABLE 11 DESIGN OF HORMONAL CONTRACEPTIVE
MEDICATIONS 36
TABLE 12 LONG-TERM CONTRACEPTIVE TREATMENTS 37
THE MORNING-AFTER PILL 37
The Morning-after Pill (Continued) (Continued) 38
CHAPTER FIVE MARKET ANALYSIS 39
MARKET OVERVIEW 39
MARKET OVERVIEW (CONTINUED) 40
MARKET SIZE AND FORECAST 41
TABLE 13 REVENUE FROM GENITOURINARY DISEASE DRUGS
FOR MAJOR COMPANIES, THROUGH 2016 ($ MILLIONS) 41
MARKET SIZE AND FORECAST (CONTINUED) 42
TABLE 14 FIVE-YEAR PROJECTION FOR REVENUE INCREASES IN
GENIROURINARY DRUG MARKET, THROUGH 2016 ($ MILLIONS) 43
CURRENT DRUGS IN THE MARKET 44
PIPELINE FORECAST FOR GENITOURINARY DRUGS 45
TABLE 15 DRUGS FOR GENITOURINARY DISEASE IN THE
PIPELINE WORLDWIDE, 2012 45
MARKET BY MECHANISM OF ACTION AND MODE OF DELIVERY 45
CHAPTER SIX: BENIGN PROSTATIC HYPERTROPHY (BPH) 46
OVERVIEW 46
ETIOLOGY OF BENIGN PROSTATIC HYPERTROPHY 46
ETIOLOGY OF BENIGN PROSTATIC … (CONTINUED) 47
DIAGNOSIS, TREATMENT AND MANAGEMENT 48
DRUGS BY MECHANISM OF ACTION 49
TABLE 16 MECHANISM OF ACTION OF APPROVED DRUGS FOR
BPH TREATMENT 49
DRUGS BY MECHANISM OF ACTION (CONTINUED) 50
DRUGS BY MECHANISM OF ACTION (CONTINUED) 51
D-3263 VERSUS SIPULEUCEL-T: 52
PROVENGE (SIPULEUCEL-T) MOA: 52
EPIDEMIOLOGY AND STATISTICS DATA 52
INCIDENCE OF BPH 53
TABLE 17 PERCENTAGE OF MALES (OVER FIFTY) WITH BPH AND
EXHIBITING SYMPTOMS, 2010 (MILLIONS) 54
TABLE 18 PROJECTED INCREASE IN MEN WITH SYMPTOMATIC
BPH, THROUGH 2016 (MILLIONS) 54
MANAGEMENT OF BPH 55
MECHANISM OF ACTION OF BPH DRUGS 55
MECHANISM OF ACTION OF BPH DRUGS (CONTINUED) 56
TABLE 19 MECHANISM OF ACTION OF APPROVED DRUGS FOR
BPH TREATMENT 57
MARKET ANALYSIS: REVENUES AND FORECAST 57
TABLE 20 BENIGN PROSTATIC HYPERTROPHY DRUG REVENUES,
THROUGH 2016 ($ MILLIONS) 58
TABLE 21 REVENUES FROM THE MAJOR BPH DRUGS, THROUGH
2016 ($ MILLIONS) 59
TABLE 22 PROJECTED REVENUES FOR BPH DRUGS BY REGION,
THROUGH 2016 ($ MILLIONS) 59
BPH DRUG SALES BY MECHANISM OF ACTION 60
TABLE 23 REVENUE FROM BPH DRUGS BY MECHANISM OF
ACTION, THROUGH 2016 ($ MILLIONS) 60
MAJOR PLAYERS IN BPH MARKET 61
TABLE 24 MAJOR PLAYERS IN BPH MARKET IN 2011 ($ MILLIONS) 61
MAJOR BPH DRUG PROFILES 61
TABLE 25 PROFILE OF ALPHA-BLOCKER DRUGS 62
TABLE 26 PROFILE OF 5-ALPHA-REDUCTASE INHIBITOR DRUGS 62
TABLE 27 PROFILE OF DRUGS WITH ALTERNATIVE MECHANISM
OF ACTION 63
THE PIPELINE FOR BENIGN PROSTATIC HYPERTROPHY
DRUGS IN PRECLINICAL DEVELOPMENT 63
TABLE 28 DRUG FOR BPH PRECLINICAL TRIALS 64
TABLE 28 (CONTINUED) 65
TABLE 28 (CONTINUED) 66
TABLE 28 (CONTINUED) 67
TABLE 28 (CONTINUED) 68
BPH DRUGS IN PHASE I CLINICAL TRIALS 68
TABLE 29 BPH DRUGS IN PHASE I CLINICAL TRIALS 69
TABLE 29 (CONTINUED) 70
BPH DRUGS IN PHASE II CLINICAL TRIALS 71
TABLE 30 DRUGS IN PHASE II CLINICAL TRIALS FOR BPH
TREATMENT 71
TABLE 30 (CONTINUED) 72
DRUGS IN PHASE III CLINICAL TRIALS FOR BPH
TREATMENT 72
TABLE 31 DRUGS IN PHASE III CLINICAL TRIALS FOR BPH
TREATMENT 73
BPH DRUGS PENDING FDA APPROVAL 73
TABLE 32 BPH DRUGS PENDING APPROVAL FROM U S FDA 74
DRUGS APPROVED BY THE FDA IN 2011 75
TABLE 33 FDA APPROVED DRUGS FOR BPH TREATMENT IN 2011 75
Drugs Approved by the FDA in 2011 (Continued) 76
CHAPTER SEVEN: ERECTILE DYSFUNCTION 77
OVERVIEW 77
ETIOLOGY OF ERECTILE DYSFUNCTION 78
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS DRUGS
BY MECHANISM OF ACTION (CONTINUED) 79
DIAGNOSIS, TREATMENT AND MANAGEMENT 79
MECHANISM OF ACTION 80
EPIDEMIOLOGICAL AND STATISTICAL DATA 80
INCIDENCE OF ERECTILE DYSFUNCTION 81
TABLE 34 PROJECTED INCREASE IN ERECTILE DYSFUNCTION,
THROUGH 2016 (MILLIONS) 81
MECHANISM OF ACTION 82
TABLE 35 CURRENT DRUGS FOR ERECTILE DYSFUNCTION
TRATMENT 82
MARKET ANALYSIS AND FORECAST 83
TABLE 36 REVENUES FOR ERECTILE DYSFUNCTION DRUGS,
THROUGH 2016 ($ MILLIONS) 83
REGIONAL FORECAST FOR ED REVENUES 84
TABLE 37 FORECAST REVENUE INCREASE FROM ERECTILE
DYSFUNCTUION DRUGS, THROUGH 2016 ($ MILLIONS) 84
TABLE 38 REVENUES AND MARKET SHARE APPROVED ERECTILE
DYSFUNCTION DRUGS, 2011 AND 2016 ($ MILLIONS/%) 84
DRUG REVENUES BY MECHANISM OF ACTION 85
MAJOR PLAYERS IN THE ERECTILE DYSFUNCTION MARKET 85
TABLE 39 MAJOR COMPANIES IN THE ERECTILE DYSFUNCTIOMN
DRUG MARKET, 2011 ($ MILLIONS/%) 86
PROFILE OF ERECTILE DYSFUNCTION DRUGS 86
TABLE 40 ERECTILE DYSFUNCTION DRUG PROFILES 86
ERECTILE DYSFUNCTION DRUG PIPELINE 87
DRUGS IN PRECLINICAL DEVELOPMENT STAGE 87
TABLE 41 DRUGS IN PRECLINICAL DEVELOPMENT 87
Drugs in Preclinical … (Continued) 88
DRUGS IN PHASE I CLINICAL TRIALS 89
TABLE 42 ERECTILE DYSFUNCTION DRUGS IN PHASE I CLINICAL
TRIAL 89
DRUGS IN PHASE II CLINICAL TRIALS 90
TABLE 43 ERECTILE DYSFUNCTION DRUGS IN PHASE II
CLINICAL TRIALS 90
TABLE 43 (CONTINUED) 91
Drugs in Phase II Clinical Trials (Continued) 92
DRUGS IN PHASE III CLINICAL TRIALS 93
TABLE 44 ERECTILE DYSFUNCTION DRIUGS IN PHASE III
CLINICAL TRIALS 93
TABLE 44 (CONTINUED) 94
ERECTILE DYSFUNCTION DRUGS PENDING FDA
APPROVAL 95
TABLE 45 ERECTILE DYSFUNCTION DRUGS PENDING FDA
APPROVAL 95
Erectile Dysfunction Drugs Pending … (Continued) 96
CHAPTER EIGHT: URINARY INCONTINENCE AND OVERACTIVE
BLADDER 97
OVERVIEW 97
STRESS INCONTINENCE 98
URGE INCONTINENCE 98
OVERFLOW INCONTINENCE 98
MIXED INCONTINENCE 98
FUNCTIONAL INCONTINENCE 99
TOTAL INCONTINENCE 99
DIAGNOSIS, TREATMENT AND MANAGEMENT 99
TABLE 46 DRUGS FOR TREATMENT OF INCONTINENCE AND
OVERACTIVE BLADDER 100
DRUG REVENUE BY MECHANISM OF ACTION 101
EPIDEMOLOGY AND STATISTICAL DATA 102
INCIDENCE OF INCONTINENCE AND OVERACTIVE
BLADDER 102
TABLE 47 INCIDENCE OF INCONTINENCE AND OVERACTIVE
BLADDER 102
MARKET ANALYSIS: SALES AND FORECASTS 103
TABLE 48 GLOBAL REVENUES FOR INCONTINENCE AND
OVERACTIVE BLADDER DRUGS, THROUGH 2016 ($ MILLIONS) 103
THE U S MARKET FOR INCONTINENCE AND OVERACTIVE
BLADDER DRUGS 104
TABLE 49 THE U S AND EUROPEAN MARKETS FOR
INCONTINENCE/OVERACTIVE BLADDER DRUGS, THROUGH
2016 ($ MILLIONS) 104
REVENUE FROM IC/OB DRUGS BY COUNTRY OR REGION 105
TABLE 50 REVENUES FROM IC/OB DRUGS BY COUNTRY OR
REGION, THROUGH 2016 ($ MILLIONS) 105
MAJOR PLAYERS IN THE INCONTINENCE OVERACTIVE
BLADDER DRUG SEGMENT 105
TABLE 51 MAJOR PLAYERS IN THE U S INCONTINENCE AND
OVERACTIVE BLADDER DRUG MARKET BY MARKET SHARE,
2011 ($ MILLIONS/%) 105
PROFILE OF THE APPROVED IC/OB DRUGS 106
TABLE 52 PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE
MARKET 106
TABLE 53 PROFILE OF THE FDA APPROVED IC/OB DRUGS ON THE
MARKET 106
COMPANY PIPELINES FOR INCONTINENCE/OVERACTIVE
BLADDER DRUGS 107
PIPELINE DRUGS FOR IC IN PRECLINICAL
DEVELOPMENT PHASE 107
TABLE 54 URINARY INCONTINENACE DRUGS IN PRECLINICAL
DEVELOPMENT 107
TABLE 54 (CONTINUED) 108
PIPELINE DRUGS FOR IC IN PHASE I CLINICAL TRIALS 109
TABLE 55 PIPELINE DRUGS FOR IC IN PHASE I CLINICAL TRIALS 109
PIPELINE DRUGS FOR IC IN PHASE II CLINICAL TRIALS 109
TABLE 56 PIPELINE DRUGS FOR IC IN PHASE II CLINICAL TRIALS 110
PIPELINE DRUGS FOR OVERACTIVE BLADDER 111
PIPELINE FOR OVERACTIVE BLADDER DRUGS IN
PRECLINICAL DEVELOPMENT 111
TABLE 57 PIPELINE FOR OVERACTIVE BLADDER DRUGS IN
PRECLINICAL DEVELOPMENT 111
TABLE 57 (CONTINUED) 112
PIPELINE FOR OB DRUGS IN PHASE I CLINICAL TRIALS 113
TABLE 58 PIPELINE FOR OB DRUGS IN PHASE I CLINICAL TRIALS 113
TABLE 58 (CONTINUED) 114
PIPELINE FOR OB DRUGS IN PHASE II CLINICAL TRIALS 115
TABLE 59 PIPELINE FOR OB DRUGS IN PHASE II CLINICAL
TRIALS 115
TABLE 59 (CONTINUED) 116
TABLE 59 (CONTINUED) 117
PIPELINE FOR OB DRUGS IN PHASE III CLINICAL TRIALS 118
TABLE 60 PIPELINE FOR OB DRUGS IN PHASE III TRIALS 118
TABLE 60 (CONTINUED) 119
PIPELINE FOR OB DRUGS IN PENDING FDA APPROVAL 120
TABLE 61 PIPELINE FOR OB DRUGS PENDING FDA APPROVAL 120
TABLE 61 (CONTINUED) 121
Pipeline for OB Drugs in … (Continued) 122
CHAPTER NINE: INFERTILITY 123
INFERTILITY OVERVIEW 123
DIAGNOSIS, TREATMENT AND MANAGEMENT 124
TABLE 62 CAUSES OF INFERTILITY IN WOMEN AND MEN 125
FEMALE INFERTILITY 125
MALE INFERTILITY 126
Male Infertility (Continued) 127
Male Infertility (Continued) 128
INFERTILITY DRUGS BY MECHANISM OF ACTION 129
TABLE 63 INFERTILITY DRUGS BY MECHANISM OF ACTION 129
EPIDEMIOLOGICAL AND STATISTICAL DATA 129
INCIDENCE OF INFERTILITY 130
TABLE 64 PROJECTED INCIDENCE OF INFERTILITY FOR THE
PERIOD, THROUGH 2016 131
MARKET ANALYSIS: SALES AND FORECAST 131
TABLE 65 REVENUES FROM INFERTILITY DRUGS, THROUGH 2016
($ MILLIONS) 132
SALES BY MECHANISM OF ACTION 133
TABLE 66 MECHANISM OF ACTION OF INFERTILITY DRUGS BY
2011 REVENUE (%) 133
MAJOR PLAYERS IN THE INFERTILITY MARKET 133
TABLE 67 MAJOR PLAYERS IN THE INFERTILITY DRUG MARKET 134
INFERTILITY DRUG PROFILES 134
TABLE 68 PROFILES OF COMMON INFERTILITY DRUGS 135
TABLE 69 PROFILE OF COMMON INFERTILITY DRUGS 135
TABLE 70 PROFILE OF COMMON INFERTILITY DRUGS 136
PIPELINE FOR INFERTILITY DRUGS 136
INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL
TRIALS 136
TABLE 71 INFERTILITY DRUGS IN PHASE I OR PHASE II CLINICAL
TRIALS 137
INFERTILITY DRUGS IN PHASE II OR PHASE III CLINICAL
TRIALS 137
TABLE 72 INFERTILITY DRUGS IN PHASE II OR PHASE III
CLINICAL TRIALS 138
MALE INFERTILITY DRUGS IN PHASE I OR PHASE II
CLINICAL TRIALS 138
TABLE 73 MALE INFERTILITY DRUGS IN PHASE I OR PHASE II
CLINICAL TRIALS 139
Male Infertility Drugs in Phase I… (Continued) 140
CHAPTER TEN: HORMONAL CONTRACEPTION 141
OVERVIEW 141
ETIOLOGY OF HORMONAL CONTRACEPTION 141
ORAL CONTRACEPTIVES 142
TABLE 74 DOSING SCHEDULES OF HORMONAL CONTRACEPTIVE
MEDICATIONS 143
TABLE 75 SUMMARYOF LONG-TERM CONTRACEPTIVE
TREATMENTS 144
THE MORNING-AFTER PILL 144
EPIDEMIOLOGY AND STATISTICAL DATA 145
INCIDENCE OF HORMONAL CONTRACEPTIVE USE 146
TABLE 76 USE OF HORMONAL CONTRACEPTIVE METHODS IN
SELECTED COUNTRIES (THOUSANDS) 146
MARKET ANALYSIS AND FORECAST 146
TABLE 77 REVENUES FROM HORMONAL CONTRACEPTION
DRUGS, THROUGH 2016 ($ MILLIONS) 147
REVENUE FOR HORMONAL CONTRACEPTION BY COUNTRY 148
TABLE 78 REVENUE FOR HORMONAL CONTRACEPTION BY
COUNTRY/REGION, THROUGH 2016 ($ MILLIONS) 148
MAJOR PLAYERS IN HORMONAL CONTRACEPTION DRUGS 148
TABLE 79 MAYOR PLAYERS IN THE HORMONAL CONTRACEPTION
MARKET 148
TABLE 79 (CONTINUED) 149
TABLE 80 REVENUES OF MAJOR PLAYERS IN THE HORMONAL
CONTRACEPTION MARKET, THROUGH 2016 ($ MILLIONS) 149
TABLE 81 PROFILE FOR COMMON DRUGS FOR HORMONAL
CONTRACEPTION 150
TABLE 82 PROFILE FOR COMMON DRUGS FOR HORMONAL
CONTRACEPTION 150
PIPELINE FOR HORMONAL CONTRACEPTION DRUGS 150
PIPELINE FOR HC DRUGS IN DEVELOPMENT, PHASE I, II
CLINICAL TRIALS 151
TABLE 83 HC DRUGS IN DEVELOPMENT, PHASE I, II CLINICAL
TRIALS 151
TABLE 83 (CONTINUED) 152
PIPELINE FOR HC DRUGS IN PHASE III CLINICAL TRIAL 153
TABLE 84 PIPELINE FOR HC DRUGS IN PHASE III CLINICAL
TRIALS 153
TABLE 84 (CONTINUED) 154
TABLE 84 (CONTINUED) 155
PIPELINE FOR HC DRUGS PENDING FDA APPROVAL 155
TABLE 85 PIPELINE FOR HC DRUGS PENDING FDA APPROVAL 156
Pipeline for HC Drugs Pending FDA approval (Continued) 157
CHAPTER ELEVEN: GENITOURINARY INFECTION 158
OVERVIEW 158
TABLE 86 COMMON BACTERIAL SPECIES IN GENITOURINARY
INFECTIONS 159
MARKET ANALYSIS AND FORECAST 160
TABLE 87 TYPICAL BACTERIA CAUSING GENITOURINARY
INFECTION AND ANTIBIOTICS FOR THEIR TREATMENT 160
MAJOR PLAYERS IN ANTIBIOTICS MARKET 161
TABLE 88 GENITOURINARY INFECTIONS AND THE ANTIBIOTICS
USED FOR TREATMENT 161
CHAPTER TWELVE: GLOBAL GENITOURINARY DISEASE DRUG
MARKET 162
OVERVIEW 162
GLOBAL REVENUES FROM GENITOURINARY DRUGS 162
TABLE 89 GLOBAL REVENUES FROM GENITOURINARY DRUGS,
THROUGH 2016, ($ MILLIONS) 162
GLOBAL INCONTENENCE AND OVERACTIVE BLADDER
REVENUE 163
TABLE 90 GLOBAL INCONTENENCE AND OVERACTIVE BLADDER
REVENUE FORECAST, THROUGH 2016 ($ MILLIONS) 163
GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUG
REVENUES 164
TABLE 91 GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUG
REVENUES, THROUGH 2016 ($ MILLIONS) 164
GLOBAL REVENUES FROM ERECTILE DYSFUNCTION
DRUGS 164
TABLE 92 GLOBAL REVENUES FROM ERECTILE DYSFUNCTION
DRUGS, THROUGH 2016 ($ MILLIONS) 165
GLOBAL REVENUE FROM HORMONAL CONTRACEPTION 165
TABLE 93 PROJECTED GLOBAL REVENUE FROM HORMONAL
CONTRACEPTION, THROUGH 2016 ($ MILLIONS) 165
GLOBAL REVENUE FROM INFERTILITY DRUGS 166
TABLE 94 GLOBAL REVENUE FROM INFERTILITY DRUGS,
THROUGH 2016 ($ MILLIONS) 166
GENITOURINARY DRUGS ONLY AVAILABLE IN SPECIFIC
COUNTRIES 167
BENIGN PROSTATIC HYPERTROPHY DRUGS AVAILABLE
IN CHINA 167
TABLE 95 BPH DRUGS ONLY AVAILABLE IN CHINA 167
ERECTILE DYSFUNCTION DRUGS AVAILABLE IN INDIA 167
TABLE 96 ERECTILE DYSFUNCTION DRUGS AVAILABLE ONLY IN
INDIA 168
CHAPTER THIRTEEN: PATENT EXAMPLES FOR GENITOURINARY
DRUGS 169
TABLE 97 U S PATENTS FOR GENITOURINARY DRUGS 169
TABLE 97 (CONTINUED) 170
CHAPTER FOURTEEN: COMPANY PROFILES 171
AGILE THERAPEUTICS 171
PRODUCTS 171
STRATEGY 172
ALLERGAN INC 172
PRODUCTS 172
STRATGEY 173
ANTARES PHARMA INC 173
PRODUCTS 173
STRATEGY 174
ASTELLAS PHARMACEUTICALS US INC 174
PRODUCTS 174
STRATEGY 175
BAYER HEALTHCARE PHARMACEUTICALS 175
PRODUCTS 176
STRATEGY 176
BOEHRINGER-INGELHEIM GMBH 176
PRODUCTS 177
STRATEGY 177
DONG-A PHARMACEUTICAL CO LTD 177
PRODUCTS 178
STRATEGY 178
ELI LILLY COMPANY 178
PRODUCTS 179
STRATEGY 179
ENDO LABORATORIES 179
PRODUCTS 179
STRATEGY 180
FERRING PHARMACEUTICALS S A 180
PRODUCTS 181
STRATEGY 181
GLAXOSMITHKLINE 181
PRODUCTS 182
STRATEGY 182
KISSEI PHARMACEUTICAL CO LTD 183
PRODUCTS 183
MERCK & CO 183
PRODUCTS 184
TABLE 98 MERCK & CO, GENITOURINARY DRUG PRODUCTS 184
STRATEGY 184
MERCK SERONO S A 185
PRODUCTS 185
STRATEGY 186
NOVARTIS INTERNATIONAL AG 186
PRODUCTS 187
TABLE 99 WOMEN'S HEALTH PRODUCTS FROM NOVARTIS 187
STRATEGY 188
NYMOX PHARMACEUTICAL CORPORATION 188
PRODUCTS 188
PFIZER CORPORATION 189
PRODUCTS 189
STRATEGY 190
PREGLEM S A 190
PRODUCTS 191
STRATEGY 191
RECORDATI S P A 192
PRODUCTS 192
ROTTAPHARM SPA 192
PRODUCTS 193
TEVA PHARMACEUTICALS INDUSTRIES LTD 193
PRODUCTS 194
STRATEGY 194
VIVUS PHARMACEUTICALS INC 194
PRODUCTS 195
STRATGEY 195
WARNER-CHILCOTT PLC 195
PRODUCTS 196
TABLE 100 WARNER CHILCOTT PRODUCTS FOR WOMEN'S
HEALTH 196
STRATEGY 197
WATSON PHARMACEUTICALS 197
PRODUCTS 197
STRATEGY 198
To order this report:Drug and Medication Industry: Genitourinary Drugs: Technologies and Global MarketsMore
Market Research ReportCheck our
Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article